These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22161994)

  • 1. An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments.
    Cobb B; Vilchez RA
    Hepatology; 2012 Mar; 55(3):979-80; author reply 980-1. PubMed ID: 22161994
    [No Abstract]   [Full Text] [Related]  

  • 2. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
    Ghany MG; Nelson DR; Strader DB; Thomas DL; Seeff LB;
    Hepatology; 2011 Oct; 54(4):1433-44. PubMed ID: 21898493
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid virological response: is it four or eight weeks?
    Milazzo L; Foschi A; Antinori S
    Hepatology; 2012 Mar; 55(3):979; author reply 980-1. PubMed ID: 22161760
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy of chronic hepatitis C: protease inhibitors significantly increase rate of healing].
    Stiefelhagen P; Einecke D
    MMW Fortschr Med; 2011 Jul; 153(29-31):14-5. PubMed ID: 21834169
    [No Abstract]   [Full Text] [Related]  

  • 5. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.
    Moucari R; Forestier N; Larrey D; Guyader D; Couzigou P; Benhamou Y; Voitot H; Vidaud M; Seiwert S; Bradford B; Zeuzem S; Marcellin P
    Gut; 2010 Dec; 59(12):1694-8. PubMed ID: 20861007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.
    Fernández-Yunquera A; Rincón D; Salcedo M; Bañares R
    Rev Esp Quimioter; 2013 Sep; 26(3):189-92. PubMed ID: 24080883
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical practice. Chronic hepatitis C infection.
    Rosen HR
    N Engl J Med; 2011 Jun; 364(25):2429-38. PubMed ID: 21696309
    [No Abstract]   [Full Text] [Related]  

  • 8. Protease inhibitors in hepatitis C: from chronic disease to cure.
    Iqbal M; McCormick PA
    Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: The new Canadian Association for the Study of the Liver HCV guidelines.
    Renner EL; Schreiber RA
    Can J Gastroenterol Hepatol; 2015 Apr; 29(3):164. PubMed ID: 25714088
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of hepatitis C infection. A revolution should not hide another].
    Sogni P
    Presse Med; 2014 Apr; 43(4 Pt 1):339-40. PubMed ID: 24661837
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
    Swiss Association for the Study of the Liver
    Swiss Med Wkly; 2012; 142():w13516. PubMed ID: 22367957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].
    Manns M
    MMW Fortschr Med; 2011 Jul; 153(29-31):17. PubMed ID: 21830729
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase 3 study results released for telaprevir and HCV.
    AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hepatitis C is curable. Even slightly elevated liver enzymes need further examination].
    Niederau C
    MMW Fortschr Med; 2008 Mar; 150(13):26. PubMed ID: 18522352
    [No Abstract]   [Full Text] [Related]  

  • 16. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
    de Bruijne J; Thomas XV; Rebers SP; Weegink CJ; Treitel MA; Hughes E; Bergmann JF; de Knegt RJ; Janssen HL; Reesink HW; Molenkamp R; Schinkel J
    J Viral Hepat; 2013 Nov; 20(11):779-89. PubMed ID: 24168257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Conclusions].
    Pineda JA
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():49-50. PubMed ID: 24063903
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C virus: Promising discoveries and new treatments.
    Bastos JC; Padilla MA; Caserta LC; Miotto N; Vigani AG; Arns CW
    World J Gastroenterol; 2016 Jul; 22(28):6393-401. PubMed ID: 27605875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.
    Hazuda DJ; Burroughs M; Howe AY; Wahl J; Venkatraman S
    Ann N Y Acad Sci; 2013 Jul; 1291():69-76. PubMed ID: 23859802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.